	US 12,012,459 B2
	OX40-binding polypeptides and uses thereof
John C. Timmer, San Diego, CA (US); William Crago, San Diego, CA (US); Kyle Jones, San Marcos, CA (US); Katelyn Willis, San Diego, CA (US); Florian Sulzmaier, San Diego, CA (US); Bryan Becklund, San Diego, CA (US); and Brendan P. Eckelman, Encinitas, CA (US)
Assigned to Inhibrx, Inc., La Jolla, CA (US)
Filed by Inhibrx, Inc., La Jolla, CA (US)
Filed on Aug. 8, 2022, as Appl. No. 17/818,106.
Application 17/818,106 is a division of application No. 16/538,216, filed on Aug. 12, 2019, granted, now 11,447,556.
Claims priority of provisional application 62/718,106, filed on Aug. 13, 2018.
Prior Publication US 2023/0128188 A1, Apr. 27, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); C12N 15/85 (2006.01)

CPC C07K 16/2875 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C12N 15/85 (2013.01); C07K 2317/569 (2013.01); C12N 2015/8518 (2013.01)]

39 Claims

1. A method of treating cancer comprising administering to a subject with cancer a pharmaceutically effective amount of a polypeptide comprising at least three VHH domains that bind OX40 and an Fc region, wherein each VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and wherein the VHH domain comprises a FR2 comprising the amino acid sequence of SEQ ID NO: 22, wherein the cancer is selected from solid cancer, hematological cancer, or lymphatic cancer.